FDA
-
-
-
-
-
-
-
Veracyte (VCYT) Reports New Data from Phase 3 Trial Further Validating Prognostic Value of Decipher Prostate Genomic Classifier
-
-
-
-
-
-
-
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
-
-
-
-
-
-
-
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
-
-
-
-
-
-
-
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
-
-
-
-
-
-
-
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
-
-
-
-
-
-
-
Veracyte (VCYT) Reports Strong Phase 3 Data of Decipher Prostate Genomic Classifier
-
-
-
-
-
-
-
Veracyte (VCYT) Announces Publication of Data Validating Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

